NASDAQ$NUWE
Nuwellis Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Nuwellis experienced revenue growth and margin expansion.
Nuwellis reported a 42% increase in revenue for Q4 2022, reaching $2.3 million, and a gross margin of 56.9%, up 250 basis points year-over-year. The company's net loss for the quarter was $1.9 million, which includes $2.6 million of Other Income related to the year-end revaluation of warrants.
- Revenue increased by 42% to $2.3 million compared to the prior-year period.
- Gross margin improved to 56.9%, a 250 basis point increase from the same period last year.
- Pediatrics, Heart Failure, and Critical Care segments led revenue growth, increasing by approximately 92%, 47%, and 24%, respectively.
- Cash, cash equivalents, and marketable securities totaled $18.3 million with no debt as of December 31, 2022.
Headline financials
Revenue & EPS history
Nuwellis · Revenue · Quarterly
$2.34M
Forward guidance
Nuwellis is focused on executing key strategic growth initiatives, including expanding the commercial team, investing in market penetration, and leveraging clinical evidence to drive sales momentum in 2023.
Tailwinds
- Targeted expansion of the commercial team
- Investments in market penetration initiatives
- Leverage of growing body of clinical evidence
- Drive continued sales momentum
- Making Aquadex the standard of care for patients with fluid overload
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-5.5%
Avg return
Earnings day
-10.5%
Avg return
5 days after
-16.7%
Avg return
30 days after
28%
15 / 54 earnings
Positive
+51.9%
Q1 2024
Best reaction
-29.9%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -5.0% | — | |
| Q4 2025 | +2.4% | -2.3% | -16.3% | |
| Q3 2025 | -3.4% | -11.9% | -18.0% | |
| Q2 2025 | +0.4% | +8.4% | -24.0% | |
| Q1 2025 | -3.1% | -5.1% | -68.7% | |
| Q4 2024 | -4.0% | -7.9% | -25.4% | |
| Q3 2024 | +6.6% | -0.6% | -28.2% | |
| Q2 2024 | -14.3% | -30.2% | -46.4% | |
| Q1 2024 | +51.9% | +47.1% | +29.4% | |
| Q4 2023 | -20.7% | -18.3% | -36.7% | |
| Q3 2023 | -10.0% | -12.9% | -14.3% | |
| Q2 2023 | -5.1% | -3.0% | -22.2% | |
| Q1 2023 | -29.9% | -37.8% | -34.6% | |
| Q4 2022 | -5.1% | -6.5% | -41.2% | |
| Q3 2022 | -19.6% | -16.7% | -50.0% | |
| Q2 2022 | -6.5% | -4.2% | +23.9% | |
| Q1 2022 | +1.0% | +2.9% | -7.4% | |
| Q4 2021 | -1.2% | -6.1% | +2.0% | |
| Q3 2021 | -17.0% | -13.2% | -33.3% | |
| Q2 2021 | +9.6% | +7.9% | +3.0% | |
| Q1 2021 | -14.6% | -8.9% | +6.6% | |
| Q4 2020 | +5.7% | -6.2% | -21.3% | |
| Q3 2020 | -7.8% | -7.0% | +14.1% | |
| Q2 2020 | -16.0% | -32.0% | -68.0% | |
| Q1 2020 | -9.6% | -14.6% | +2.4% | |
| Q4 2019 | -28.8% | -33.9% | -29.0% | |
| Q3 2019 | -15.0% | -23.0% | -16.0% | |
| Q2 2019 | -1.2% | +2.0% | +0.4% | |
| Q1 2019 | -13.3% | -13.3% | -24.9% | |
| Q4 2018 | -12.6% | -25.6% | -69.8% | |
| Q3 2018 | +2.8% | +4.7% | -21.7% | |
| Q2 2018 | -26.4% | -37.4% | -23.9% | |
| Q1 2018 | -17.1% | -18.8% | -23.3% | |
| Q4 2017 | -15.5% | -25.7% | -21.0% | |
| Q3 2017 | -12.8% | -15.6% | -47.3% | |
| Q2 2017 | -4.0% | -13.3% | -6.7% | |
| Q1 2017 | -9.5% | -1.4% | -9.5% | |
| Q4 2016 | -5.3% | -12.0% | -58.0% | |
| Q3 2016 | -5.0% | -5.0% | +190.0% | |
| Q2 2016 | -14.9% | -16.0% | -17.0% | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | -15.9% | — | — | |
| Q3 2015 | -1.2% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -3.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -17.5% | — | — | |
| Q2 2014 | +23.9% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | +2.1% | — | — | |
| Q1 2013 | +6.2% | — | — | |
| Q4 2012 | +2.6% | — | — | |
| Q2 2012 | -7.6% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro